Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: Long-term results from the DUO Registry

Annals of the Rheumatic Diseases

Volumn 75, Issue 10, 2016, Pages 1770-1776

  Matucci Cerinic, Marco ^a   Krieg, Thomas ^b   Guillevin, Loic ^c   Schwierin, Barbara ^d   Rosenberg, Daniel ^d   Cornelisse, Peter ^d   Denton, Christopher P ^e  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Institut Cochin   (France)

^d ACTELION PHARMACEUTICALS LTD   (Switzerland)

^e ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Autoimmune Diseases; Epidemiology; Systemic Sclerosis

Indexed keywords

ADULT; AGED; CHRONIC DISEASE; CLASSIFICATION; CLINICAL TRIAL; COMPLICATION; COST OF ILLNESS; DAILY LIFE ACTIVITY; DISABILITY; FEMALE; FINGER; FOLLOW UP; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; QUESTIONNAIRE; RECURRENT DISEASE; REGISTER; SKIN ULCER; SYSTEMIC SCLEROSIS;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; CHRONIC DISEASE; COST OF ILLNESS; DISABILITY EVALUATION; FEMALE; FINGERS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; REGISTRIES; SCLERODERMA, SYSTEMIC; SKIN ULCER; SURVEYS AND QUESTIONNAIRES;

EID: 85008478803     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208121     Document Type: Article

References (23)

1. Hinchcliff M, Varga J. Systemic sclerosis/scleroderma: a treatable multisystem disease. Am Fam Physician 2008; 78: 961-8.
2. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis 2013; 72: 1747-55.
3. Nihtyanova NI, Brough GM, Black CM, et al. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2008; 67: 120-3.
4. Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66: 754-63.
5. Steen V, Denton CP, Pope JE, et al. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 2009; 48(Suppl 3): iii19-24.
6. Merkel PA, Herlyn K, Martin RW, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002; 46: 2410-20.
7. Hachulla E, Clerson P, Launay D, et al. Natural history of ischemic digital ulcers in systemic sclerosis: a single-center retrospective longitudinal study. J Rheumatol 2007; 34: 2423-30.
8. Mouthon L, Mestre-Stanislas C, Bérezné A, et al. Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis 2010; 69: 214-17.
9. Mihai C, Landewé R, van der Heijde D, et al. Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis 2015; Published Online First 16 Feb 2014.
10. Herrick AL, Roberts C, Tracey A, et al. Lack of agreement between rheumatologists in defining digital ulceration in systemic sclerosis. Arthritis Rheum 2009; 60: 878-82.
11. Amanzi L, Braschi F, Fiori G, et al. Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatology (Oxford) 2010; 49: 1374-82.
12. Actelion Pharmaceuticals Ltd. Tracleer Summary of Product Characteristics. 2013. http://www. ema. europa. eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/000401/WC500041597. pdf (accessed Dec 2014).
13. Guillevin L, Hunsche E, Denton CP, et al. Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry. Clin Exp Rheumatol 2013; 31(2 Suppl 76): 71-80.
14. Sjogren R. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994; 37: 1265-82.
15. Sunderkötter C, Herrgott I, Brückner C, et al. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol 2009; 160: 835-43.
16. Guillen-Del Castillo A, Pilar Simeón-Aznar C, et al. Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM/Scl antibody. Semin Arthritis Rheum 2014; 44: 331-7.
17. Steen VD, Powell DL, Medsger TA. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31: 196-203.
18. Briggs DC, Vaughan RW, Welsh KI, et al. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991; 338: 661-2.
19. Ingraham K, Steen V. Morbidity of digital tip ulceration in scleroderma. Arthritis Rheum 2006; 54(Suppl 9): 578.
20. Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 2012; 24: 165-70.
21. Cozzi F, Tiso F, Lopatriello S, et al. The social costs of digital ulcer management in scleroderma patients: an observational Italian pilot study. Joint Bone Spine 2010; 77: 83-4.
22. Brand M, Hollaender R, Rosenberg D, et al. An observational cohort study of patients with newly diagnosed digital ulcer disease secondary to systemic sclerosis registered in the EUSTAR database. Clin Exp Rheumatol 2015; 33(4 Suppl 91): S47-54.
23. Xu D, Li M-T, Hou Q, et al. Clinical characteristics of systemic sclerosis patients with digital ulcers in China. Clin Exp Rheumatol 2013; 31(Suppl 76): S46-9.